Jul 23, 2024
|
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
|
|
Jun 4, 2024
|
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
|
|
May 20, 2024
|
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
|
|
May 14, 2024
|
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
|
|
May 9, 2024
|
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
|
|
Apr 18, 2024
|
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
|
|
Mar 20, 2024
|
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
|
|
Mar 8, 2024
|
CEO Update: Lumos Pharma Celebrates International Women’s Day
|
|
Mar 7, 2024
|
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
|
|
Feb 26, 2024
|
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
|
|